IP Library Granted Patent US 9,969,677
Granted Patent B2
US 9,969,677 · App. 13/996,483 · Granted May 15, 2018

Histone acetyltransferase modulators and uses thereof

Inventors: Yitshak Francis (New York, NY); Mauro Fa (New York, NY); Ottavio Arancio (New York, NY); Jole Fiorito (New York, NY); Shixian Deng (White Plains, NY); Donald W. Landry (New York, NY); Michal Luzac (New York, NY); Yan Feng (Shanghai, CN)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
C07C217/22C07D209/48C07D265/14C07D295/088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,969,677
App. No.
13/996,483
Granted
May 15, 2018
Kind
B2
Abstract

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

Claims (27)

1. A compound of any one of the formulae below:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition, comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

4. A pharmaceutical composition, comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition, comprising the compound of claim 5 , and at least one pharmaceutically acceptable carrier.

13. A pharmaceutical composition, comprising the compound of claim 6 , and at least one pharmaceutically acceptable carrier.

14. A pharmaceutical composition, comprising the compound of claim 7 , and at least one pharmaceutically acceptable carrier.

15. A pharmaceutical composition, comprising the compound of claim 8 , and at least one pharmaceutically acceptable carrier.

16. A pharmaceutical composition, comprising the compound of claim 9 , and at least one pharmaceutically acceptable carrier.

17. A pharmaceutical composition, comprising the compound of claim 10 , and at least one pharmaceutically acceptable carrier.

18. A pharmaceutical composition, comprising the compound of claim 11 , and at least one pharmaceutically acceptable carrier.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 13, 2017
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044427/0792 →
Continuity (4)
Provisional Application 61426033 · Dec 22, 2010
Provisional Application 61539697 · Sep 27, 2011
Provisional Application 61541706 · Sep 30, 2011
Related Publication 20170121276A1 · May 4, 2017